Pain Therapeutics Revamps Oxytrex Program, Changes Phase III Protocol For Pain
This article was originally published in Pharmaceutical Approvals Monthly
Pain Therapeutics' new trial design for Oxytrex features ultra-low doses and a four-times-a-day dosing regimen, CEO Remi Barbier said May 4
You may also be interested in...
Inappropriate enrollment of former Vioxx patients in Pain Therapeutics’ Phase III trial of Oxytrex for severe osteoarthritic pain undermined the study’s statistical power and necessitates a new trial, according to PTI.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011